Moshe Giladi - Novocure Chief Officer
| NVCR Stock | USD 19.18 0.14 0.72% |
Executive
Moshe Giladi is Chief Officer of Novocure
| Age | 54 |
| Address | Neuhofstrasse 21, Baar, Switzerland, 6340 |
| Phone | 44 15 3475 6700 |
| Web | https://www.novocure.com |
Moshe Giladi Latest Insider Activity
Tracking and analyzing the buying and selling activities of Moshe Giladi against Novocure stock is an integral part of due diligence when investing in Novocure. Moshe Giladi insider activity provides valuable insight into whether Novocure is net buyers or sellers over its current business cycle. Note, Novocure insiders must abide by specific rules, including filing SEC forms every time they buy or sell Novocure'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Moshe Giladi over three months ago Disposition of 2779 shares by Moshe Giladi of Novocure at 69.37 subject to Rule 16b-3 | ||
Moshe Giladi over three months ago Disposition of 831 shares by Moshe Giladi of Novocure at 107.73 subject to Rule 16b-3 | ||
Moshe Giladi over three months ago Disposition of 831 shares by Moshe Giladi of Novocure at 107.73 subject to Rule 16b-3 | ||
Moshe Giladi over three months ago Disposition of 831 shares by Moshe Giladi of Novocure at 107.73 subject to Rule 16b-3 |
Novocure Management Efficiency
The company has return on total asset (ROA) of (0.0877) % which means that it has lost $0.0877 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4667) %, meaning that it created substantial loss on money invested by shareholders. Novocure's management efficiency ratios could be used to measure how well Novocure manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/21/2025, Return On Tangible Assets is likely to drop to -0.14. In addition to that, Return On Capital Employed is likely to drop to -0.37. At this time, Novocure's Non Current Assets Total are relatively stable compared to the past year. As of 03/21/2025, Non Currrent Assets Other is likely to grow to about 15.3 M, while Net Tangible Assets are likely to drop slightly above 267.8 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Ahmet Tezel | LivaNova PLC | N/A | |
| Matt Rodgers | InMode | N/A | |
| Miriam Provost | TransMedics Group | 64 | |
| Marc Rosenbaum | iRhythm Technologies | 52 | |
| Chad Patterson | iRhythm Technologies | 42 | |
| MD FSIR | Penumbra | N/A | |
| Andrew Isaacson | Insulet | N/A | |
| Deborah CPA | Insulet | 53 | |
| Douglas Devine | iRhythm Technologies | 54 | |
| Catherine Szyman | Masimo | 58 | |
| Martin Abrams | Inspire Medical Systems | N/A | |
| Nick Corcoran | TransMedics Group | 42 | |
| Ben Tompkins | Penumbra | N/A | |
| Carlton Weatherby | Inspire Medical Systems | 39 | |
| Pankaj Tiwari | Penumbra | N/A | |
| Kimberly Lockwood | CONMED | N/A | |
| Badri Amurthur | LivaNova PLC | N/A | |
| Gerardo Hernandez | TransMedics Group | N/A | |
| Daniel Esq | CONMED | 60 | |
| Mervin Smith | iRhythm Technologies | 49 | |
| Patrick Crannell | Insulet | N/A | |
Management Performance
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.0877 |
Novocure Leadership Team
Elected by the shareholders, the Novocure's board of directors comprises two types of representatives: Novocure inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novocure. The board's role is to monitor Novocure's management team and ensure that shareholders' interests are well served. Novocure's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novocure's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Barak BenArye, General Counsel | ||
| William Burke, Chief Officer | ||
| Frank Leonard, Executive Oncology | ||
| Christoph Brackmann, Chief Officer | ||
| Asaf Danziger, CEO and Director | ||
| Uri MD, Chief Officer | ||
| Piet MD, Head VP | ||
| Pritesh Shah, Chief Commercial Officer | ||
| Ashley Cordova, Chief Officer | ||
| Moshe Giladi, Chief Officer | ||
| Wilhelmus Groenhuysen, Chief Officer | ||
| Pr MD, Founder CTO | ||
| MBA MD, Chief Officer | ||
| Ingrid Goldberg, VP Relations | ||
| Barak Arye, General Counsel | ||
| Mukund Paravasthu, Chief Officer | ||
| William Doyle, Executive Chairman | ||
| Michael Puri, Chief Officer |
Novocure Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novocure a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.0877 | ||||
| Profit Margin | (0.28) % | ||||
| Operating Margin | (0.39) % | ||||
| Current Valuation | 1.83 B | ||||
| Shares Outstanding | 109.92 M | ||||
| Shares Owned By Insiders | 9.70 % | ||||
| Shares Owned By Institutions | 84.85 % | ||||
| Number Of Shares Shorted | 5.2 M | ||||
| Price To Earning | 721.15 X |
Additional Tools for Novocure Stock Analysis
When running Novocure's price analysis, check to measure Novocure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novocure is operating at the current time. Most of Novocure's value examination focuses on studying past and present price action to predict the probability of Novocure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novocure's price. Additionally, you may evaluate how the addition of Novocure to your portfolios can decrease your overall portfolio volatility.